Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
Authors:
- For The Alzheimer’s Disease Neuroimaging InitiativeFIFor The Alzheimer’s Disease Neuroimaging Initiative
- Li ShenLSLi Shen
- Paul M. ThompsonPTPaul M. Thompson
- Steven G. PotkinSPSteven G. Potkin
- Lindsay A. FarrerLFLindsay A. Farrer
- John S. K. KauweJKJohn S. K. Kauwe
Open Access
- 5 October 2013
- journal article
- review article
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 8 (2) , 183-207
Abstract
The Genetics Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), formally established in 2009, aims to provide resources and facilitate research related to genetic predictors of multidimensional Alzheimer’s disease (AD)-related phenotypes. Here, we provide a systematic review of genetic studies published between 2009 and 2012 where either ADNI APOE genotype or genome-wide association study (GWAS) data were used. We review and synthesize ADNI genetic associations with disease status or quantitative disease endophenotypes including structural and functional neuroimaging, fluid biomarker assays, and cognitive performance. We also discuss the diverse analytical strategies used in these studies, including univariate and multivariate analysis, meta-analysis, pathway analysis, and interaction and network analysis. Finally, we perform pathway and network enrichment analyses of these ADNI genetic associations to highlight key mechanisms that may drive disease onset and trajectory. Major ADNI findings included all the top 10 AD genes and several of these (e.g., APOE, BIN1, CLU, CR1, and PICALM) were corroborated by ADNI imaging, fluid and cognitive phenotypes. ADNI imaging genetics studies discovered novel findings (e.g., FRMD6) that were later replicated on different data sets. Several other genes (e.g., APOC1, FTO, GRIN2B, MAGI2, and TOMM40) were associated with multiple ADNI phenotypes, warranting further investigation on other data sets. The broad availability and wide scope of ADNI genetic and phenotypic data has advanced our understanding of the genetic basis of AD and has nominated novel targets for future studies employing next-generation sequencing and convergent multi-omics approaches, and for clinical drug and biomarker development.Keywords
This publication has 161 references indexed in Scilit:
- Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE RegionArchives of Neurology, 2012
- Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer DiseaseArchives of Neurology, 2012
- Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer DiseaseArchives of Neurology, 2012
- Genome-wide and gene-based association implicates FRMD6 in alzheimer diseaseHuman Mutation, 2011
- Association and Expression Analyses With Single-Nucleotide Polymorphisms in TOMM40 in Alzheimer DiseaseArchives of Neurology, 2011
- Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE GenotypesArchives of Neurology, 2010
- Genetic pathway‐based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- Genetic Variation and Neuroimaging Measures in Alzheimer DiseaseArchives of Neurology, 2010
- Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's diseaseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010
- Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnnals of Neurology, 2010